Market expansion for nasal medication delivery systems is anticipated to be fueled by an increase in product approvals by regulatory bodies. For instance, the U.S. Food and Medication Administration (FDA) approved Aptar Pharma's Bidose nasal spray device for use as a ground-breaking treatment for depression on March 18, 2019, according to the company's announcement. Aptar Pharma is a developer of drug delivery systems. Additionally, naloxone hydrochloride nasal spray is a prescription drug used to treat an opioid emergency, such as an overdose or a probable opioid overdose with symptoms like breathing difficulties or an inability to respond.
Global Nasal Drug Delivery Systems Market is estimated to be valued at US$ 60.3 million in 2022 and is expected to exhibit a CAGR of 6.3% during the forecast period (2022-2030).
Top Companies in the Nasal Drug Delivery Systems Industry:
1. Merck & Co., Inc.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
2. GlaxoSmithKline plc
GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom. GSK plc and Wave Life Sciences Ltd in December, 2022 announced a strategic collaboration to advance oligonucleotide therapeutics, including Wave’s preclinical RNA editing programme targeting alpha-1 antitrypsin deficiency (AATD), WVE-006.
3. AstraZeneca plc
AstraZeneca PLC was incorporated in 1992.The company is headquartered in Cambridge, the United Kingdom and operational in more than 100 countries. AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. In December, 2022 AstraZeneca’s Calquence (acalabrutinib), a selective Bruton’s tyrosine kinase (BTK) inhibitor, has been approved in Japan for the treatment of adult patients with treatment-naïve chronic lymphocytic leukaemia (CLL)
4. Johnson & Johnson
Johnson & Johnson Services, Inc.is the largest and most broadly based healthcare company as it is present in more than 60 countries. It has headquarters in New Brunswick, NJ.
5. Pfizer Inc.
Pfizer Inc. was founded in 1849 and is headquartered in New York, New York. Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sell biopharmaceutical products worldwide. In December, 2022 announced the U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine as the third 3-µg dose in the three-dose primary series for children 6 months through 4 years of age.
6. Baxter International, Inc.
Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois. The company is operational in more than 100 countries.
7. Becton, Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company was founded in 1897 and is based in Franklin Lakes, New Jersey. In January, 2023 BD (Becton, Dickinson and Company) introduced a new, robotic track system for the BD Kiestra™ microbiology laboratory solution that automates lab specimen processing, which may help to reduce manual labor and wait time for results.
8. Novartis AG.
The company was incorporated in 1996 and is headquartered in Basel, Switzerland. Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. Novartis in December, 2022 announced the European Commission (EC) approved Pluvicto® (INN: lutetium (177Lu) vipivotide tetraxetan), a targeted radioligand therapy.
*Definition- A nasal medicine delivery device offers direct access to systemic circulation as an option to invasive administrations.
